Trademark: 90788388
Word
BIOHAVEN PHARMACEUTICALS
Status
Registered
Status Code
700
Status Date
Tuesday, January 25, 2022
Serial Number
90788388
Registration Number
6629316
Registration Date
Tuesday, January 25, 2022
Mark Type
3000
Filing Date
Tuesday, June 22, 2021
Published for Opposition
Tuesday, November 9, 2021

Trademark Owner History
Biohaven Therapeutics Ltd. - Original Registrant

Classifications
5 Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in Amyotrophic Lateral Sclerosis (ALS), pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in Alzheimer's disease (AD), disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine for the adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use
42 Pharmaceutical research and development in the fields of headache, facial pain, impulse control disorders, neurological disorders, and neurodegenerative disorders, and consultation provided in conjunction therewith
The mark consists of the stylized wording "BIOHAVEN PHARMACEUTICALS", with two outlined hexagon shapes positioned above the letter "I" and one outlined hexagon shape positioned below the letter "I", and the wording "PHARMACEUTICALS" appearing in smaller print below the wording "BIOHAVEN".
"PHARMACEUTICALS"

Trademark Events
Apr 17, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 17, 2023
Teas Change Of Correspondence Received
Apr 17, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 17, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 17, 2023
Teas Change Of Owner Address Received
Jun 23, 2022
Assignment Of Ownership Not Updated Automatically
Jan 25, 2022
Registered-Principal Register
Jan 12, 2022
Assignment Of Ownership Not Updated Automatically
Nov 9, 2021
Official Gazette Publication Confirmation E-Mailed
Nov 9, 2021
Published For Opposition
Oct 20, 2021
Notification Of Notice Of Publication E-Mailed
Oct 6, 2021
Approved For Pub - Principal Register
Sep 21, 2021
Teas/Email Correspondence Entered
Sep 21, 2021
Correspondence Received In Law Office
Sep 21, 2021
Teas Response To Office Action Received
Sep 10, 2021
Notification Of Non-Final Action E-Mailed
Sep 10, 2021
Non-Final Action E-Mailed
Sep 10, 2021
Non-Final Action Written
Sep 8, 2021
Assigned To Examiner
Sep 8, 2021
Notice Of Design Search Code E-Mailed
Sep 7, 2021
New Application Office Supplied Data Entered
Jun 25, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24